Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock

19 Mar 2026, 21:30 by Jessica Moore · The Cerbat Gem

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) insider Yu-Waye Chu sold 21,279 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $136,611.18. Following the completion of the sale, the insider owned 189,446 shares in the company, valued at approximately $1,216,243.32. This trade represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

CytomX Therapeutics Stock Up 8.3%

CTMX stock traded up $0.37 during mid-day trading on Thursday, hitting $4.77. 13,412,791 shares of the company were exchanged, compared to its average volume of 11,334,038. The firm has a market capitalization of $810.96 million, a P/E ratio of -119.13 and a beta of 2.44. The business has a fifty day simple moving average of $5.28 and a 200-day simple moving average of $4.10. CytomX Therapeutics, Inc. has a 12-month low of $0.40 and a 12-month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last released its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. The company had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $7.33 million. Research analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Key CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

Positive Sentiment: Several brokerages raised ratings/targets, boosting sentiment — Barclays raised its target to $16 (overweight). Article Title
Positive Sentiment: Guggenheim increased its price target to $15 and kept a Buy rating, supporting upside expectations. Article Title
Positive Sentiment: Wedbush raised its price target to $11, and JPMorgan reportedly upgraded the stock — multiple upgrades are driving positive analyst momentum. Wedbush Article JPMorgan Article
Neutral Sentiment: HC Wainwright cut near‑term EPS forecasts (Q1–Q4 2026 and FY2026/2027) but retained a Buy rating and a $17 target — mixed signal (lowered estimates but continued bullish view). MarketBeat Report
Neutral Sentiment: Short-interest data in the feed appears anomalous (shows zero shares) and likely does not provide meaningful directional signal today.
Negative Sentiment: CytomX priced an underwritten offering of common stock and pre‑funded warrants to raise up to $250M gross (closing expected March 19); markets often view such equity raises as dilutive, which can pressure the stock despite providing runway for trials. Offering Release
Negative Sentiment: Related coverage notes net proceeds of about $234M from the offering — confirms material dilution magnitude and why some traders sold into the raise. TipRanks Article
Negative Sentiment: Insider selling: CFO Christopher Ogden sold 19,323 shares and SVP Marcia Belvin sold 31,492 shares on March 17 — disclosed on SEC Form 4 filings; insider sales can be read negatively by the market. CFO Form 4 SVP Form 4
Negative Sentiment: Recent quarterly results missed expectations (EPS and revenue), which was cited as a reason for an intra‑day pullback earlier this week. Earnings Reaction

Wall Street Analysts Forecast Growth

A number of research firms have commented on CTMX. Guggenheim upped their price target on CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays lifted their price objective on CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday. HC Wainwright increased their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday. Jefferies Financial Group raised their target price on CytomX Therapeutics from $8.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald lifted their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, CytomX Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $13.22.

Check Out Our Latest Stock Report on CTMX

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors have recently modified their holdings of the business. Orbimed Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the second quarter worth $19,208,000. Commodore Capital LP purchased a new position in CytomX Therapeutics in the second quarter valued at $17,462,000. Perceptive Advisors LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth $15,876,000. Franklin Resources Inc. purchased a new stake in CytomX Therapeutics during the 2nd quarter worth about $13,096,000. Finally, Vivo Capital LLC purchased a new stake in CytomX Therapeutics during the 2nd quarter worth about $13,096,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

(Get Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.